Paternal exposure to antidiabetic medications during reproductive period and adverse birth outcomes: A meta-analysis and systematic review
Abstract
Background: Diabetes affected approximately 6% of all adults globally in 2021, and the use of antidiabetic medications is expected to increase among men of reproductive age. The impact of paternal exposure to these medications during spermatogenesis on offspring is still unclear.
Objective: To review the association between paternal use of antidiabetic medications during spermatogenesis and adverse birth outcomes.
Data sources: On 27 January 2025, a systematic search of Medline, Embase and Cochrane libraries was conducted without restriction on publication year, supplemented by a manual search. Study selection and synthesis: Population-based studies examining paternal preconception exposure to antidiabetic medications compared with non-exposed fathers were included. Study quality and validity were assessed using the MOOSE guidelines, and synthesis used fixed- and random-effects models. The Oxford Centre for Evidence-Based Medicine and risk-of-bias tools were also used.
Main outcome: Congenital malformations.
Results: Of 2859 studies identified, four met the inclusion criteria. Two studies (2,435,462 births analysed) linked metformin to congenital malformations [adjusted odds ratio (aOR) 1.40, 95 % confidence interval (CI) 1.08-1.82; p = 0.012; adjusted hazard ratio 1.4, 95 % CI 1.11-1.76]. The common-effect model for metformin and congenital malformations was non-significant (aOR 1.05, 95 % CI 0.95-1.17) with high heterogeneity (I2 = 76.9 %) (p = 0.0017).
Conclusion and…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.